It is expected that in Dec 2018 quarter, Citizens Financial Group, Inc. (NYSE:CFG) will have an EPS of $0.94, while that of Mar 2019 is projected at $0.87. It means that there could be a 32.39% and 11.54% growth in the two quarters respectively. Yearly earnings are expected to rise by 36.43% to about $3.52. As for the coming year, growth will be about 9.38%, lifting earnings to $3.85. RSI after the last trading period was 30.97. CFG recorded a change of -7.27% over the past week and returned -17.99% over the last three months while the CFG stock’s monthly performance revealed a shift in price of -10.47%. The year to date (YTD) performance stands at -19.53%, and the bi-yearly performance specified an activity trend of -19.4% while the shares have moved -17.39% for the past 12 months.
CFG’s EPS was $0.93 as reported for the September quarter. In comparison, the same quarter a year ago had an EPS of $0.68. That means that its growth in general now stands at 37%. Therefore, a prediction of $0.9 given by the analysts brought a positive surprise of 3%. CFG Sep 18 quarter revenue was $1.56 billion, compared to $1.44 billion recorded in same quarter last year, giving it a 8% growth rate. The company’s $0.12 billion revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.
Citizens Financial Group, Inc. (CFG) currently trades at $33.78, which is lower by -1.92% its previous price. It has a total of 475.96 million outstanding shares, with an ATR of around 1.04. The company’s stock volume rose to 7.83 million, better than 4.92 million that represents its 50-day average. A 5-day decrease of about -7.27% in its price means CFG is now -19.53% lower on year-to-date. The shares had marked a $48.23 52-week high price and the 52 week low of $34.07. Overall, it has seen a growth rate of -17.39 over the last 12 months.
17 analysts out of 22 Wall Street brokerage firms rate CFG stock as a Buy, while 0 see it as a Sell. The rest 5 describe it as a Hold. The stock traded higher to an intra-day high of $34.25. At one point in session, its potential discontinued and the price was down to lows at $33. Analysts have set CFG’s consensus price at $46.34, effectively giving it a 37.18% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $53 (up 56.9% from current price levels). CFG has a 9.6% ROE, lower than the 16.94% average for the industry. The average ROE for the sector is 16.43%.
AstraZeneca PLC (NYSE:AZN) shares depreciated -2.51% over the last trading period, taking overall 5-day performance up to -3.12%. CFG’s price now at $38.87 is weaker than the 50-day average of $39.36. Getting the trading period increased to 200 days, the stock price was seen at $37.1 on average. The general public currently hold control of a total of 2.52 billion shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 2.53 billion. The company’s management holds a total of 0.5%, while institutional investors hold about 18.2% of the remaining shares. CFG share price finished last trade -3.57% below its 20 day simple moving average and its upbeat gap from 200 day simple moving average is 4.84%, while closing the session with -1.24% distance from 50 day simple moving average.
AstraZeneca PLC (AZN) shares were last observed trading -6.95% down since November 13, 2018 when the peak of $41.78 was hit. Last month’s price growth of -0.31% puts AZN performance for the year now at 12.02%. Consequently, the shares price is trending higher by 21.51%, a 52-week worst price since Dec. 07, 2017. However, it is regaining value with 6.9% in the last 6 months.
AZN’s beta is 0.53; meaning investors could reap lower returns, although it also poses lower risks. The company allocated $0.97 per share from its yearly profit to its outstanding shares. Its last reported revenue is $5.34 billion, which was -14% versus $6.23 billion in the corresponding quarter last year. The EPS for Sep 18 quarter came in at $0.35 compared to $0.56 in the year-ago quarter and had represented -38% year-over-year earnings per share growth. AZN’s ROA is 3.9%, lower than the 11.98% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 11.5%.
Analysts estimate full-year growth to be -60.75%, the target being $1.68 a share. The upcoming year will see an increase in growth by percentage to 9.52%, more likely to see it hit the $1.84 per share. The firm’s current profit margin over the past 12 months is 11.3%. AZN ranks higher in comparison to an average of 11.16% for industry peers; while the average for the sector is 2.16%.